Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORDANA G FEIN

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1841463098
CMS profile
38661
Location
MANASSAS, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$123,449.27

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORDANA G FEIN

NPI 1841463098 · CMS profile ID 38661

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

MANASSAS, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841463098?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORDANA G FEIN, NPI 1841463098, CMS profile ID 38661. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841463098?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JORDANA G FEIN, NPI 1841463098, CMS profile ID 38661. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841463098?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JORDANA G FEIN, NPI 1841463098, CMS profile ID 38661, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841463098?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $123,449.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $52.0002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061208116 CMS
Genentech USA, Inc. $529.1002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061208118 CMS
Genentech USA, Inc. $303.9702/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061208120 CMS
Genentech USA, Inc. $5,300.0002/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061208122 CMS
Genentech USA, Inc. $57.8502/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061208124 CMS
Regeneron Healthcare Solutions, Inc. $342.8002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999169229 CMS
Genentech, Inc. $15.7202/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040410865 CMS
Apellis Pharmaceuticals, Inc. $17.9602/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056370317 CMS
Regeneron Healthcare Solutions, Inc. $25.0402/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999169225 CMS
Dompe US, Inc. $124.7401/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055250567 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/19/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056358659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,093.27 59
PY2020 $22,743.97 15
PY2021 $5,921.64 18
PY2022 $41,174.46 61
PY2023 $123,449.27 111
PY2024 $92,904.63 90
PY2025 $70,313.40 80

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,276.80 2
PY2025 Principal investigator $361,890.13 198
PY2024 Principal investigator $496,827.76 264
PY2023 Recipient $6,958.93 3
PY2023 Principal investigator $265,089.93 67
PY2022 Principal investigator $191,586.81 38
PY2021 Principal investigator $122,546.76 31
PY2020 Principal investigator $26,870.79 5
PY2019 Principal investigator $33,848.11 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

200 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $1,456.32 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240345
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240347
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240349
Principal investigator 1 Ocular Therapeutix, Inc. $900.00 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240355
Principal investigator 1 Ocular Therapeutix, Inc. $14,582.00 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240357
Principal investigator 1 Ocular Therapeutix, Inc. $3,300.00 12/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240359
Principal investigator 1 Ocular Therapeutix, Inc. $73,557.90 12/12/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240335
Principal investigator 1 Ocular Therapeutix, Inc. $37.91 12/01/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240333
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 11/19/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 11/17/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261635
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364437
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364439
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364441
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364443
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364445
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364447
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364449
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364451
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364455
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364457
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364459
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 11/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364461
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,500.00 10/29/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410054
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 10/29/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410194
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $550.00 10/29/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410210
Principal investigator 1 KYOWA KIRIN, INC. $3,235.52 10/27/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813263
Principal investigator 1 KYOWA KIRIN, INC. $3,064.45 10/27/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813271
Principal investigator 1 KYOWA KIRIN, INC. $3,064.45 10/27/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813282
Principal investigator 1 Apellis Pharmaceuticals, Inc. $300.00 10/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364429
Principal investigator 1 Apellis Pharmaceuticals, Inc. $158.00 10/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364431
Principal investigator 1 Apellis Pharmaceuticals, Inc. $384.00 10/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364435
Principal investigator 1 Apellis Pharmaceuticals, Inc. $553.00 10/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364427
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/09/2025 Non-covered Recipient Entity
The Retina Group of Washington (RGW) - Chevy Chase
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240231
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 10/03/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410102
Principal investigator 1 KYOWA KIRIN, INC. $500.00 09/25/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810813
Principal investigator 1 KYOWA KIRIN, INC. $200.00 09/25/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810819
Principal investigator 1 Notal Vision, Inc. $30.00 09/16/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753951
Principal investigator 1 Notal Vision, Inc. $30.00 09/16/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753973
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $216.62 09/08/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410522
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $169.83 09/08/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411278
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $145.74 09/08/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411392
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $288.39 09/08/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411474
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 09/08/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411476
Principal investigator 1 Apellis Pharmaceuticals, Inc. $250.00 09/03/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364249
Principal investigator 1 KYOWA KIRIN, INC. $250.00 08/28/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 08/13/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184226927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/13/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184226929
Principal investigator 1 Notal Vision, Inc. $30.00 08/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753863
Principal investigator 1 Notal Vision, Inc. $60.00 08/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753885
Principal investigator 1 Notal Vision, Inc. $30.00 08/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753907
Principal investigator 1 Notal Vision, Inc. $30.00 08/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 08/11/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184226619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 08/11/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184226621
Principal investigator 1 Apellis Pharmaceuticals, Inc. $300.00 08/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364251
Principal investigator 1 KYOWA KIRIN, INC. $5,828.33 08/04/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808951
Principal investigator 1 KYOWA KIRIN, INC. $3,217.70 08/04/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808958
Principal investigator 1 Apellis Pharmaceuticals, Inc. $200.00 08/01/2025 Non-covered Recipient Entity
Total Practice Management LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364421
Principal investigator 1 Notal Vision, Inc. $30.00 07/24/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753841
Principal investigator 1 Apellis Pharmaceuticals, Inc. $300.00 07/18/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364277
Principal investigator 1 Apellis Pharmaceuticals, Inc. $395.00 07/18/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364279
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364265
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364267
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364269
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364271
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364273
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 07/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364275
Principal investigator 1 Apellis Pharmaceuticals, Inc. $250.00 07/11/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364257
Principal investigator 1 Apellis Pharmaceuticals, Inc. $316.00 07/11/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364259
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 06/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364389
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364391
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364393
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364395
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364397
Principal investigator 1 Apellis Pharmaceuticals, Inc. $640.00 06/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364387
Principal investigator 1 Notal Vision, Inc. $30.00 06/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753775
Principal investigator 1 Notal Vision, Inc. $60.00 06/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753797
Principal investigator 1 Notal Vision, Inc. $30.00 06/12/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753819
Principal investigator 1 Apellis Pharmaceuticals, Inc. $258.00 06/11/2025 Non-covered Recipient Entity
Total Practice Management LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364369
Principal investigator 1 Apellis Pharmaceuticals, Inc. $300.00 06/11/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364375
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 06/11/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408444
Principal investigator 1 Notal Vision, Inc. $30.00 06/10/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753685
Principal investigator 1 Notal Vision, Inc. $30.00 06/10/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753707
Principal investigator 1 Notal Vision, Inc. $60.00 06/10/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753729
Principal investigator 1 Notal Vision, Inc. $30.00 06/10/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/29/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184200261
Principal investigator 1 Notal Vision, Inc. $30.00 05/23/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753641
Principal investigator 1 Notal Vision, Inc. $30.00 05/23/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753663
Principal investigator 1 KYOWA KIRIN, INC. $500.00 05/19/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805707
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 05/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364401
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 05/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364403
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 05/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364405
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 05/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.00 05/15/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 05/15/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195859
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 05/14/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240325
Principal investigator 1 Ocular Therapeutix, Inc. $12,500.00 05/14/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.40 05/12/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194447
Recipient Regeneron Pharmaceuticals, Inc. $1,828.00 05/10/2025 Covered Recipient Physician EYLEA CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117441
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,550.00 05/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364361
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405722
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406308
Principal investigator 1 Apellis Pharmaceuticals, Inc. $200.00 04/23/2025 Non-covered Recipient Entity
Total Practice Management LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364359
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 04/16/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364379
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $941.16 04/16/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404251
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $941.16 04/16/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406968
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $36.92 04/09/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405126
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $48.34 04/03/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404249
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,596.20 04/02/2025 Non-covered Recipient Entity
Total Practice Management LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364351
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/02/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404247
Recipient Regeneron Pharmaceuticals, Inc. $448.80 03/31/2025 Covered Recipient Physician EYLEA CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117439
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 03/24/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404696
Principal investigator 1 Notal Vision, Inc. $30.00 03/19/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753619
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 03/17/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404253
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364309
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364311
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364313
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364315
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364317
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364319
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364321
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364323
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364325
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364327
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364329
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364331
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 03/14/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364333
Principal investigator 1 Notal Vision, Inc. $30.00 03/11/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.51 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $593.65 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $406.03 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $502.59 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.51 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.55 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $506.04 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $499.18 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $505.26 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.03 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $470.97 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $415.55 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.55 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $506.04 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $505.26 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.03 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $499.18 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $415.55 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $496.51 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $470.97 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $408.69 03/07/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164373
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403853
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403855
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405724
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405726
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405728
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406216
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406970
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 02/27/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406972
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 02/19/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364283
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 02/19/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364285
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 02/19/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364287
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 02/19/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364289
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 02/19/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364291
Principal investigator 1 Notal Vision, Inc. $30.00 02/17/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753529
Principal investigator 1 Notal Vision, Inc. $30.00 02/17/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753553
Principal investigator 1 Notal Vision, Inc. $30.00 02/17/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753575
Principal investigator 1 KYOWA KIRIN, INC. $5,806.68 02/14/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801147
Principal investigator 1 KYOWA KIRIN, INC. $5,806.68 02/14/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801154
Principal investigator 1 Notal Vision, Inc. $60.00 02/14/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753463
Principal investigator 1 Notal Vision, Inc. $30.00 02/14/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753485
Principal investigator 1 Notal Vision, Inc. $30.00 02/14/2025 Non-covered Recipient Entity
Total Practice Management, LLC
NRICH No dispute reported 06/30/2026 1242753507
Principal investigator 1 Alexion Pharmaceuticals, Inc. $28,281.30 02/12/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185547407
Principal investigator 1 Apellis Pharmaceuticals, Inc. $158.00 02/07/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364305
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402665
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402667
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403303
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404243
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404245
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404471
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,604.36 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404852
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,296.04 01/30/2025 Non-covered Recipient Entity
Total Practice Management
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406618
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364337
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364339
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364341
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364343
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364345
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,205.00 01/24/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364347
Principal investigator 1 Apellis Pharmaceuticals, Inc. $300.00 01/15/2025 Non-covered Recipient Entity
Total Practice Management LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364307
Principal investigator 1 KYOWA KIRIN, INC. $250.00 01/03/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221798774
Principal investigator 1 KYOWA KIRIN, INC. $250.00 01/03/2025 Non-covered Recipient Entity
TOTAL PRACTICE MANAGEMENT
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221798779